arbiter
JournalsPricingAccount

Regulating Direct‐to‐Consumer Prescription Drug Advertising in the United States

Jennifer L. Pomeranz et al.

The Milbank Quarterly2026https://doi.org/10.1111/1468-0009.70071article
AJG 3ABDC B
Weight
0.50

What the paper says

Congress should provide FDA with equal authority over compounded drug promotion as it has for prescription drug promotion. FDA should issue regulations or guidance on modern forms of DTC advertising. The learned intermediary is based on outdated concepts and should be reconsidered by state legislatures and courts.

Open paper page →

Cite this paper

https://doi.org/https://doi.org/10.1111/1468-0009.70071

Or copy a formatted citation

@article{jennifer2026,
  title        = {{Regulating Direct‐to‐Consumer Prescription Drug Advertising in the United States}},
  author       = {Jennifer L. Pomeranz et al.},
  journal      = {The Milbank Quarterly},
  year         = {2026},
  doi          = {https://doi.org/https://doi.org/10.1111/1468-0009.70071},
}

Paste directly into BibTeX, Zotero, or your reference manager.

Flag this paper

Regulating Direct‐to‐Consumer Prescription Drug Advertising in the United States

Flags are reviewed by the Arbiter methodology team within 5 business days.

Evidence weight

0.50

Balanced mode · F 0.40 / M 0.15 / V 0.05 / R 0.40

F · citation impact0.50 × 0.4 = 0.20
M · momentum0.50 × 0.15 = 0.07
V · venue signal0.50 × 0.05 = 0.03
R · text relevance †0.50 × 0.4 = 0.20

† Text relevance is estimated at 0.50 on the detail page — for your query’s actual relevance score, open this paper from a search result.